The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and BioCentury RFK Jr.'s peptide deregulation threatens the foundations of drug safety Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA to weigh easing limits on unproven peptides